Overall survival following HSCT with or without malignancy in modern-era trials
| Post-HSCT overall survival . | Without malignancy . | With malignancy . |
|---|---|---|
| SCN | ||
| *EBMT39 | 87% (n = 73) | 79% (n = 14) |
| *SCNIR (European)40 | 78% (n = 27) | 83% (n = 24) |
| SDS | ||
| ^CIBMTR42 | 72% (n = 39) | 15% (n = 13) |
| ^SAAWP-EBMT41 | 71% (n = 61) | 29% (n = 13) |
| *SDSR43 | — | 46% (n = 15) |
| Post-HSCT overall survival . | Without malignancy . | With malignancy . |
|---|---|---|
| SCN | ||
| *EBMT39 | 87% (n = 73) | 79% (n = 14) |
| *SCNIR (European)40 | 78% (n = 27) | 83% (n = 24) |
| SDS | ||
| ^CIBMTR42 | 72% (n = 39) | 15% (n = 13) |
| ^SAAWP-EBMT41 | 71% (n = 61) | 29% (n = 13) |
| *SDSR43 | — | 46% (n = 15) |
Three-year overall survival; ^five-year overall survival.
CIBMTR, Center for International Blood and Marrow Transplant Research; EBMT, European Society for Bone Marrow Transplantation; SAAWP-EMBT, Severe Aplastic Anemia Working Party of the EBMT; SCNIR, Severe Chronic Neutropenia International Registry; SDSR, Shwachman-Diamond Syndrome Registry of North America.